¶ Pfizer-BioNTech COVID-19 vaccine
The Pfizer-BioNTech COVID-19 vaccine is a series of mRNA-based gene therapy products marketed as vaccines against COVID-19. The term is used to describe multiple versions of the product developed by Pfizer and BioNTech. Its official brand name is Comirnaty.
While initally referring primarily to BNT162b2 (the original formulation authorized for mass distribution) the names "Pfizer-BioNTech COVID-19 vaccine" and "Corminaty" are increasingly used to refer to subsequent reformulated versions, including those for the XBB.1.5 variant of SARS-CoV-2.
¶ National contracts
Albania
Between Pfizer, the Albanian Ministry of Health and Social Protection and the Institute of Public Health in Albania.
- January 6, 2021: Manufacturing and Supply Agreement
Brazil
Between Pfizer and the Ministry of Health of Brazil.
- March 18, 2021: Purchase Agreement
Canada
Between Pfizer and the Minister of Public Works and Government Services Canada on behalf of Public Services and Procurement Canada.
- October 26, 2020: Manufacturing and Supply Agreement
South Africa
Between Pfizer and the National Department of Health of South Africa.
- March 30, 2021: Manufacturing and Supply Agreement
- June 4, 2021: Amendment to Manufacturing and Supply Agreement
- Binding Term Sheet
¶ Product monographs
Canada
- September 28, 2023: COMIRNATY® Omicron XBB.1.5